KDR and neoplasm: Sunitinib is a marketed VEGFR inhibitor with excellent anti-tumor activities against gastrointestinal stromal tumors, neuroendocrine tumors, renal cell carcinoma and pancreatic and breast cancers, while it is primarily an indolin-2-one derivative [16].